Boehringer Ingelheim Venture Fund

The BIVF was formed in March 2010 to invest in biotechnology and start-up companies to help drive innovation in medical science. These may include novel technologies to address so far new therapeutic targets, new generation vaccines and new biological entities, such as antibody-dependent oncolysis. Additional focuses are novel therapeutic targets, disease-related biomarkers and new approaches in regenerative medicine.


Bpifrance's equity investments are operated by Bpifrance Investissement. Bpifrance invests directly or indirectly in small, medium and large French companies. InnoBio is a €173m fund managed by Bpifrance and subscribed to by the French sovereign fund FSI and key global pharmaceutical companies (Sanofi-aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda, Boehringer-Ingelheim) operating in France. The main objective of the fund is to directly invest equity or partial equity in the capital of firms providing innovative and technological products and services in the health sector.

Cap Decisif Management

Cap Decisif Management is an early-stage and seed venture capital fund. It invests in all sectors of innovative and high-tech companies in IT, health and life sciences / biotechnologies, engineering, energy and environment, and clean tech. Cap Decisif Management invests in the first round, as sole investor or as a leader, in innovative companies and technology start-ups with high growth potential.

Inserm Transfert

Founded in 2010, InsermTransfert SA is the private subsidiary of the French National Institute of Health and Medical Research (Inserm), dedicated to technology transfer. InsermTransfert also supports entrepreneurs in the biotech sector through its dedicated seed fund ITI.

Pontifax Venture Capital

Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with over $350 million under management. Pontifax focuses on transformative, cutting-edge life sciences technologies at all development stages. Their portfolio comprises over 40 companies that develop breakthrough solutions to substantial unmet needs.

Pureos Bioventures

Pureos Bioventures strives to impact patients’ lives by advancing innovative treatments for severe diseases. Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and drug formats.

GHS Fund

Global Health Sciences Fund was jointly established by Quark Venture LP and GF Securities in 2016. Global Health Sciences Fund is a health sciences venture fund that invests globally in a diversified portfolio of innovative biotechnology and health sciences companies that are addressing unmet medical needs through innovations in drug development, medical devices, health IT and emerging convergent technologies.